

# RESTRATA

Synthetic Hybrid-Scale Fiber Matrix


## Restrata is engineered to be structurally similar to native human extracellular matrix<sup>5</sup>







Human Tissue



Xenogenic Collagen

#### Restrata hybrid-scale fiber matrix features:

- Fiber size and structure supports cellular ingrowth and retention<sup>1,2</sup>
- Porosity supports granulation and vascularization<sup>2</sup>
- Controlled resorption rate via hydrolysis<sup>2</sup>
- Resistant to enzymatic degradation<sup>2</sup>
- Excellent biocompatibility<sup>1, 2</sup>
- Tensile strength similar to human skin<sup>1</sup>
- Slightly acidic byproducts, potentially lowering pH of local microenvironment<sup>4</sup>

**85**% of wounds treated with Restrata achieved **complete closure** at 12 weeks, with an average time to complete wound healing of 4.8 +/- 3.0 weeks<sup>3</sup>

Closure in multiple wound types <sup>3</sup>	All wounds (n=82)	DFUs (n=34)	VLUs (n=34)	Other wounds (n=14)
Complete wound closure at 6 weeks Number of wounds, n (%)	53 (64.6%)	21 (61.8%)	23 (67.6%)	9 (64.3%)
Complete wound closure at 12 weeks Number of wounds, n (%)	68 (85.0%)	28 (84.8%)	30 (90.9%)	10 (71.4%)
Mean ± SD	4.8 ± 3.0	4.7 ± 2.7	5.3 ± 3.4	3.7 ± 2.7




FDA clearance: April 2017



### Restrata is indicated for a variety of conditions including:<sup>5</sup>

- Surgical and trauma wounds
- · Partial and full-thickness wounds
- Acute and chronic wounds
- Tunneling and exudating wounds
- VLUs, DFUs and pressure ulcers
- Burns


Restrata demonstrated increased granulation, neovascularization and epithelialization versus Integra Bilayer Wound Matrix in a large animal model<sup>2</sup>



100% of wounds treated with Restrata were granulated after 15 days, compared to 20-50% of wounds treated with Integra Bilayer Wound Matrix<sup>2</sup>

### RESTRATA® Synthetic Hybrid-Scale Fiber Matrix

### **Size up to 10 x 12.5 cm**



Part Number	Size (cm)	Size (in)	
RWM1-1X1	2.5 x 2.5	1 x 1	
RWM1-1X2*	2.5 x 5.0	1 x 2	
RWM1-1X3	2.5 x 7.5	1 x 3	
RWM1-2X2	5.0 x 5.0	2 x 2	
RWM1-3X3	7.5 × 7.5	3 x 3	
RWM1-4X5*	10.0 x 12.5	4 x 5	

\*Available as open market purchase items in VA facilities.

#### **How to Order**

Call/fax Acera Customer Service (844) 879-2237

Or visit acera-surgical.com


FSS #V797P-36F79718D0525



Acera Surgical, Inc. ("Acera," St. Louis, MO) is a bioscience company commercializing a portfolio of synthetic hybrid-scale fiber matrices for medical applications.



#### Serving our veterans



#### Restrata is easy to use

- Terminally sterilized
- Two-year shelf life
- No human or animal tissue components—no special storage and handling requirements
- Six available sizes to reduce waste and cost
- ✓ No requirement for specific orientation when implanting
- Suitable for use in patients with specific ethnic or religious objections to tissue grafts
- Store at ambient temperature for off-the-shelf use

### Restrata is easy to apply

- **Select** appropriate size
- 2. Fenestrate if desired
- 3. Cut to fit
- 4. Hydrate as needed
- 5. Fixate with Steri-Strips, staples, or sutures

#### References

- 1. MacEwan MR, MacEwan S, Kovacs TR, et al. (October 2, 2017) What Makes the Optimal Wound Healing Material? A Review of Current Science and Introduction of a Synthetic Nanofabricated Wound Care Scaffold. Cureus Journal of Medical Science 9(10): e1736. doi:10.7759/cureus.1736
- 2. MacEwan MR, MacEwan S, Wright AP, et al. (August 27, 2017) Comparison of a Fully Synthetic Electrospun Matrix to a Bi-Layered Xenograft in Healing Full Thickness Cutaneous Wounds in a Porcine Model. Cureus Journal of Medical Science 9(8): e1614. doi:10.7759/cureus.1614
- 3. Regulski M, MacEwan M; Implantable Nanomedical Scaffold Facilitates Healing of Chronic Lower Extremity Wounds, Wounds, August 2018: Vol 30, No.8
- 4. Data on file
- 5. MKG-20002 IFU